August 11, 2023 10:42 AM EDT
News Briefing

Ake­bia no­ti­fies SEC it will be late fil­ing Q2 earn­ings; Sur­rozen cuts two ear­ly pro­grams

Paul Schloesser

Associate Editor

Tyler Patchen

News Reporter

Ake­bia Ther­a­peu­tics an­nounced Fri­day that it will be late fil­ing its sec­ond-quar­ter earn­ings re­port due to “cer­tain ac­count­ing er­rors” around its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times